XML 20 R9.htm IDEA: XBRL DOCUMENT v3.25.2

BALANCE SHEET COMPONENTS

6 Months Ended

Jun. 30, 2025

BALANCE SHEET COMPONENTS

BALANCE SHEET COMPONENTS

3. BALANCE SHEET COMPONENTS

Inventories

The Company had the following major classes of inventories:

​

​	​	​	​	​	​	​
​		June 30, 2025			December 31, 2024
​	​	(amounts, in thousands)
Raw materials	​	$	491	​	$	570
Work in process	​		782	​		503
Finished goods	​		2,437	​		1,660
Inventories	​	$	3,710	​	$	2,733

​

Property and equipment, net

The Company’s property and equipment consist of the following:

​

​	​	​	​	​	​	​	​	​
​	​	​	​	​	​	​	​	Depreciation/
​	​	​	​	​	​	​	​	Amortization
​		June 30, 2025			December 31, 2024			Period
​	​	(amounts, in thousands)					​	​
Furniture and fixtures	​	$	1,599	​	$	1,454		7 years
Equipment and computers	​		5,557	​		5,491		3 to 7 years
Leasehold improvements	​		6,308	​		6,283		Lesser of term of lease or estimated useful life
​	​		13,464	​		13,228	​	​
Less accumulated depreciation and amortization	​		4,998	​		4,226
Property and equipment, net	​	$	8,466	​	$	9,002

​

Depreciation expense for the six months ended June 30, 2025 and 2024 amounted to $0.6 million and $0.8 million, respectively.

Other assets

Other assets consist of the following:

​

​	​	​	​	​	​	​
​		June 30, 2025			December 31, 2024
​	​	(amounts, in thousands)
Patent applications pending	​	$	1,722	​	$	1,612
Patents issued	​		3,391	​		3,391
Less accumulated amortization of patents issued	​		(1,374)	​		(1,255)
Patents, net	​		3,739	​		3,748
Other	​		53	​		23
Other assets	​	$	3,792	​	$	3,771

​

Patent amortization expenses amounted to $0.1 million for the six months ended June 30, 2025 and 2024.

Patent amortization expense for the next five years and thereafter is scheduled as follows:

​

​	​	​	​
​	​	(amounts, in thousands)
Remainder of 2025		$	97
2026	​		257
2027	​		251
2028	​		238
2029	​		238
Thereafter	​		936
Scheduled amortization of patents issued	​	$	2,017

​

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:

​

​	​	​	​	​	​	​
​		June 30, 2025			December 31, 2024
​	​	(amounts, in thousands)
Accrued salaries and commissions	​	$	3,397	​	$	3,076
Clinical studies	​		567	​		590
Deferred revenue	​		361	​		419
Professional fees	​	​	356	​	​	773
Royalties	​	​	287	​	​	275
Goods received not invoiced	​	​	20	​	​	87
Other	​		965	​		812
Accrued expenses and other current liabilities	​	$	5,953	​	$	6,032

​

X

- References

No definition available.

+ Details

Name:	us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/210/tableOfContent

+ Details

Name:	us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration